Business Wire

APRIL

Share
APRIL Group Launches Its Spring 2027 Strategic Plan With the Ambition of Becoming a European Leader With a Global Stature in the Mass Market

Building on the success of its first transformation plan, APRIL is embarking on a new phase in its development with the ambition of becoming a European leader of global stature in the design, distribution and management of insurance solutions and financial products. The Group is planning an ambitious growth cycle, both organic and external, which will take it to a turnover of more than €1 billion by 2027.

With sales of €630m by 2023, 20% of which will be generated outside France, the Spring 2023 strategic plan has enabled APRIL to return to its basics and achieve sustainable growth. Today, the Group is looking ahead to a new stage in its development and has set itself the target of exceeding €1 billion in turnover by 2027.

« In an extremely competitive international environment, one of the most successful insurance brokers is French! Our nearly 3,000 employees are proud to continue APRIL's history and are in action to expand our global footprint, for the benefit of our tens of thousands of partners and our millions of customers, whom we support and protect on a daily basis, » states Eric Maumy, CEO of APRIL.

Four cardinal points to guide the Group's development:
the spirit of conquest, customer delight, technological performance and talent.

The spirit of conquest to become a global consolidator

With its sustained growth, APRIL Group will further accelerate its development based on three principles:

  • Organic growth in its traditional markets: health and personal insurance for individuals, professionals and businesses, health insurance for expatriates and property and casualty insurance (auto, 2-wheeler, construction, real estate and yachting).
  • Diversification into new growth drivers, as the Group has already begun to do with savings and asset management, which have become the Group's 4th business line.
  • Internationalisation in all its markets, starting with international health, with strong ambitions in Europe, the Middle East and Asia.

In terms of diversification and internationalisation, APRIL Group intends to step up its external growth momentum, as demonstrated by the two deals completed since the beginning of 2024 with leading French savings company DLPK and UK two-wheeler specialist Lexham Insurance.

This consolidation drive will naturally go hand in hand with APRIL’s ongoing commitment to defending the interests of customers, particularly in terms of access to quality healthcare for as many people as possible.

Enchanting partners and customers to reinvent the insurance experience
Having improved its Net Promoter Score by more than 20 points in 4 years, the Group wants to accelerate its efforts to improve the experience of its partners and customers, by focusing on 3 key areas:

  • Enhancing its service approach (easier access to healthcare networks and to teleconsultation facilities, etc.);
  • Improving its digital systems - from the underwriting process to self-care areas and conversational tools;
  • Strengthening and continually training the teams in contact with customers and partners, to offer them the very best in technology and human relations.

A technological transformation that incorporates Data & AI
APRIL Group plans to invests €70 million in its digital and technological transformation by 2027 with a twofold aim :

  • Capitalising on data and artificial intelligence, via iterative projects that will be carried out within the group in France and internationally across all business lines to identify the potential for creating value for employees, customers and partners;
  • Continuing to strengthen cyber security in an environment of heightened threat to all economic players.

Providing employees with a unique experience to attract and retain talent
With an average of 400 new hires per year since 2020, APRIL Group has strengthened its team, in particular by recruiting talent in high-tension professions, notably digital technology within its APRIL X hub and customer relations.

With its ambitions raised to 2027, the Group plans to offer a structured and enriched employee experience based on 3 levers:

  • Developing talent through the knowledge factory, which will include strengthening the APRIL University and launching an Apprentice Training Centre;
  • Focusing on our employees, with several agreements on intergenerational dynamics and inclusion & diversity, as well as the relocation of the Group's head office to more modern, collaborative offices in Lyon (France);
  • Greater sharing of value, with the opening of the capital to all the Group's employees worldwide from April 2024.

True to its roots in the social economy, the Group plans to fuel its sustainable growth with a positive and real impact in terms of CSR, in particular through its APRIL Foundation, which focuses on the contribution of behavioural sciences to health prevention and promotion.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411952024/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye